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Phosphatidyl-inositol-3 kinases (PI3Ks) constitute a
family of intracellular lipid kinases that are frequently
hyperactivated in glioblastoma. The PI3K complex
links growth factor signaling with cellular proliferation,
differentiation, metabolism, and survival. Mammalian
target of rapamycin (mTOR) acts both as a downstream
effector and upstream regulator of PI3K, thus highlight-
ing its importance in glioblastoma. This review high-
lights laboratory and clinical evidence of mTOR’s role
in glioblastoma. Mechanisms of escape from mTOR
inhibition are also discussed, as well as future clinical
strategies of mTOR inhibition.
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Introduction: mTOR Signaling in
Glioblastoma
G
lioblastoma is the most common malignant
primary brain tumor in adults and one of the
most lethal of all cancers.
1 Glioblastomas
invade the surrounding brain, making complete surgical
excision highly improbable. They are also among the
most radiation therapy- and chemotherapy-resistant
cancer types, with a median survival duration of 12–
15 months afterinitial diagnosis.
2 Thus, new therapeutic
approaches are needed.
Mammalian target of rapamycin (mTOR), a key
mediator of phosphatidyl-inositol-3-kinase (PI3K)
signaling, has emerged as a compelling molecular target
in glioblastoma patients, although clinical efforts to
target mTOR have not been successful. Here, we
outline the evidence demonstrating that mTOR is a com-
pellingmoleculartargetinglioblastoma.Wefocusonthe
role of mTOR in PI3K signaling and its larger role in
metabolic cellular programs in glioblastoma. We sum-
marize the current clinical status of mTOR inhibition,
paying particular attention to resistance through study-
ing glioblastoma patients treated with the mTORC1
complex inhibitor rapamycin in phase I and II clinical
trials. We describe how the study of glioblastoma
patients has increased our understanding of the
complexity of mTOR signaling. Finally, we describe
new strategies for targeting mTOR in glioblastoma
patients.
Constitutive PI3K Pathway Activation Is a
Hallmark of Glioblastoma
PI3Ks are a family of highly conserved intracellular lipid
kinases that regulate cellular proliferation, differen-
tiation, metabolism, and survival.
3 Class IA PI3Ks are
activated by growth factor receptor tyrosine kinases
(RTKs), either directly or through interaction with the
insulin receptor substrate family of adaptor molecules.
3
This activity results in the production of phosphatidyl-
inositol-3,4,5-trisphospate (PIP3), a critical regulator
of the serine/threonine kinase Akt, which links growth
factor signaling with cellular growth, proliferation,
metabolism, and survival.
3,4
Tightly regulated PI3K signaling is essential for
normal development, whereas persistently activated
PI3K signaling is associated with the development of
cancer.
5 PI3K-activating mutations are found in nearly
all patients with glioblastoma,
6,7 as indicated by the
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pathway.
8 EGFR ampliﬁcation is detected in 45% of
glioblastoma patients, providing one common route
to PI3K pathway activation. EGFR activating mutations
are also commonly detected in EGFR-ampliﬁed glioblas-
tomas (Fig. 1).
9–11 EGFRvIII, the most common EGFR
mutation (occurring in 20%–30% of glioblastomas),
results from genomic deletion of exons 2–7.
12,13 It
lacks a ligand-binding domain, yet it is persistently acti-
vated and fails to be internalized normally, resulting in
constitutive signaling with a preferential effect on PI3K
activity in relation to the wild-type receptor.
8,14 Other
RTKs also contribute to PI3K pathway activation,
including c-MET and PDGFRa, both of which can be
co-activated in EGFR-ampliﬁed tumors
1 and confer
resistance to EGFR inhibitors by providing an alterna-
tive route for maintaining PI3K signal ﬂux.
15
Ampliﬁcation or activating mutations of the catalytic
and regulatory subunits of PI3K also contribute to PI3K
pathwayactivation in up to 10% of glioblastomas.
6 Loss
of the phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) tumor suppressor protein, the
major negative regulator of the PI3K pathway that
antagonizes PI3K signaling by dephosphorylating PIP3,
occurs in more than 50% of glioblastomas and is a
third mechanism of constitutive PI3K pathway
activation.
8,16 In addition, NF1 loss, either through
genetic inactivation
6 or enhanced proteosomal degra-
dation,
17 is a relatively common event in glioblastoma
that can lead to enhanced PI3K pathway activity.
18
Therefore, multiple PI3K-activating genetic lesions
occur in nearly all glioblastoma patients, highlighting
the biological importance of this pathway.
Consistent with the results of analyses of patient
tumor tissues, mouse genetic models indicate that consti-
tutive PI3K pathway activation may be required for
malignant glioma formation and progression.
19 In
these models, constitutive PI3K signaling cooperates
with alterations in other signaling pathways that are
also commonly activated in glioblastoma patients,
including those involving RAS/MEK/ERK, p53, and
pRB.
20–22,78,79 Other mouse genetic models demon-
strate alternative routes towards malignant glioma for-
mation that involve PI3K hyperactivation, including
mutant EGFR in combination with Ink4a/arf.
23
Further, PTEN loss cooperates with pRB loss to
promote glioma formation and progression.
24,25
Perhaps most impressively, concurrent alterations of
the same pathways identiﬁed in human glioblastomas
through gene mutation analysis, including NF1 loss,
p53 loss, and PTEN loss (including haploinsufﬁciency),
promote the formation and progression of malignant
Fig. 1. mTORC plays a key role in integrating signal transduction and metabolic pathways in glioblastoma. Schematic representation shows
pathways that regulate or are regulated by mTOR signaling in glioblastoma, with the known frequency of molecular alterations in these
genes.
6,32,67,77
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lement human tumor analyses by suggesting a causative
role for persistent PI3K pathway activation and the
accompanying mTOR signaling in the development
and progression of malignant gliomas.
mTOR as a Therapeutic Target in
Glioblastoma
mTOR acts through the canonical PI3K pathway via 2
distinct complexes, each characterized by different
binding partners that confer distinct activities. In
complex with PRAS40, raptor, and mLST8/GbL,
mTOR acts as a downstream effector of PI3K/Akt sig-
naling, linking growth factor signals with protein trans-
lation, cell growth, proliferation, and survival. This
complex is known as mTORC1. In complex with
rictor, mSIN1, protor, and mLST8 (mTORC2), mTOR
acts as an upstream activator of Akt.
26 The recently
identiﬁed negative regulator of mTOR, DEPTOR, is a
component of both the mTORC1 and mTORC2 com-
plexes.
27 Upon growth factor receptor-mediated acti-
vation of PI3K, Akt is recruited to the membrane
through the interaction of its pleckstrin homology
domain with PIP3, thus exposing its activation loop
and enabling phosphorylation at threonine 308
(Thr308) by the constitutively active phosphoinositide-
dependent protein kinase 1 (PDK1).
28–30 For maximal
activation, Akt is also phosphorylated by mTORC2, at
serine 473 (Ser473) of its C-terminal hydrophobic
motif. Akt activates mTORC1 through inhibitory phos-
phorylation of TSC2, which along with TSC1, nega-
tively regulates mTORC1 by inhibiting the Rheb
GTPase, a positive regulator of mTORC1. mTORC1
has 2 well-deﬁned substrates, p70S6K (referred to here-
afteras S6K1) and 4E-BP1, both of which critically regu-
late protein synthesis.
30 Thus, mTORC1 is an important
downstream effector of PI3K, linking growth factor
signaling with protein translation and cellular prolifer-
ation.
31 Surprisingly, an Akt-independent, PKCa-
dependent mechanism that links PI3K with mTORC1
in glioblastoma has also been described.
32 In a serial
cell line transformation model, mTORC1 signaling
through S6K1 was required for malignant glioma for-
mation, highlighting its functional importance.
33
The compelling nature of mTORC1 as a glioma
target, coupled with the relative efﬁcacy of the
mTORC1 complex inhibitor rapamycin and its deriva-
tives in preclinical mouse glioblastoma models,
34–36
has generated considerable hope for more effective tar-
geted therapy for malignant glioma patients. However,
a number of factors suggest that rapamycin-based treat-
ments are not the best choice for effectively targeting
mTOR in patients. First, mTORC1 plays a dual role as
a positive regulator of PI3K/Akt signaling from
growth factor receptors and a negative regulator of
PI3K pathway activation when signal ﬂux through
PI3K is high. This ensures homeostatic regulation of
this critical signal in healthy cells.
26 mTORC1 impairs
PI3K activation in growth factor-stimulated cells by
downregulating IRS 1 and 2 and PDGFR.
37–39 Its role
in regulating PI3K signaling downstream of EGFR is
less well understood, although the results of a recent
study suggest that an activated EGFRvIII allele enhances
feedback activation of PI3K signaling in glioblastoma
cells treated with rapamycin.
40 Derepression of
mTORC1-mediated feedback with rapamycin could
result in more rapid clinical progression in glioblastoma
patients, as described below.
41 The results of a recent
study suggest that mTORC1 has rapamycin-insensitive,
kinase-dependent activity.
42 Further, rapamycin and its
derivatives do not consistently target mTORC2, whose
function and importance is discussed below.
27
Therefore, the recent development of mTOR kinase-
speciﬁc inhibitors offers a whole new set of therapeutic
options that will need to be evaluated clinically.
26
mTORC2 signaling in glioblastomais less well under-
stood than that in mTORC1. mTORC2, which is acti-
vated by PI3K, phosphorylates Akt on serine 473
(Ser473) of its C-terminal hydrophobic motif, thereby
promoting maximal Akt activity. mTORC2 also acti-
vates additional kinases, including serum
glucocorticoid-induced protein kinase and PKCa, all of
which may play important roles in regulating cellular
proliferation and growth. mTORC2 activity has been
shown to be elevated in glioma cell lines and clinical iso-
lates, and rictor overexpression has been shown to
enhance motility and promote glioma cell proliferation
in vitro.
43 Further, in a recent Drosophila model of glio-
magenesis promoted by constitutive coactivation of
EGFR-Ras-Akt, mTORC2 activity was required for
glial proliferation. The results of these studies suggest
that mTORC2 signaling is essential for growth in the
context of enhanced signal ﬂux through the PI3K
pathway.
44 Future studies using both genetic and
pharmacological approaches will be needed to better
understand the role of mTORC2 signaling in malignant
glioma. Clearly, elucidating the molecular circuitry that
underlies mTORC1 and mTORC2 signaling will be very
important for developing more effective glioblastoma
treatments. In fact, an enriched picture of these signaling
networks began to emerge during the ﬁrst rapamycin-
based clinical trials. Below, we discuss the results of
these trials, highlighting efforts to study mechanisms of
resistance in glioma patients treated with rapamycin.
Targeting the EGFR/PI3K/mTOR Signaling
Pathway in Glioma Patients: Lessons
Learned
A number of phase I and II single-agent clinical trials of
rapamycin (and its analogue CCI-779) have been con-
ducted in malignant glioma. In addition, EGFR tyrosine
kinase inhibitor and EGFR tyrosine kinase inhibitor/
rapamycin analogue clinical trials have been
reported.
41,45–48 Although results with these agents
have been disappointing, a considerable amount has
been learned from the study of treated tumor tissue,
suggesting more effective treatment strategies.
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tors geﬁtinib and erlotinib suggest relatively low
response rates of 10%–15%.
46,49 These results are
somewhat difﬁcult to reconcile with the perceived
importance of the EGFR target. Our research group
demonstrated that constitutively active mutant
EGFRvIII expression sensitizes tumors to EGFR inhibi-
tors in vitro and clinically, but only if the PTEN tumor
suppressor protein is intact. In fact, loss of PTEN inhi-
bition of downstream PI3K signaling has been shown
to be a critical promoter of up-front resistance to
EGFR inhibitors.
45 Haas-Kogan et al.
46 demonstrated,
in vitro and in glioma patients, that high levels of
EGFR, coupled with low levels of activated Akt (a criti-
cal effector of PI3K signaling), are associated with a
favorable response. The results of these studies demon-
strate that the intact regulation of PI3K signaling is criti-
cal for an effective response to EGFR; similar results
were also found in a human serially passaged xenograft
model of glioblastoma
50 and in other cancer types.
51
Maintained signal ﬂux through PI3K, whether
through PTEN loss or RTK coactivation, is a common
mechanism of EGFR inhibitor resistance,
15 and
mTORC1 appears to be its critical effector.
32,52
Preclinical studies demonstrated that dual EGFR/
mTOR inhibition was effective at targeting
EGFR-activated PTEN deﬁcient tumors;
52–54 however,
2 small studies (one of everolimus plus geﬁtinib and
the other of rapamycin and erlotinib) in patients with
recurrent malignant glioma failed to demonstrate
durable responses.
48,55 Similarly, phase II studies of
single-agent rapalogs in recurrent glioblastoma multi-
forme have failed to demonstrate clinical efﬁcacy.
56,57
A number of possible explanations exist for the clini-
cal ineffectiveness of rapamycin and its analogues,
whether as monotherapy or in combination with
EGFR kinase inhibitors.
49,56 Typically, when a new
cancer drug enters clinical trials, it is developed empiri-
cally by ﬁrst deﬁning the maximum tolerated dose and
then assessing clinical activity across a range of diseases.
This approach may not be adequate for determining
optimal dose or assessing efﬁcacy of target inhibition
when using a drug similar to rapamycin. First, it is
anticipated that targeted agents, such as rapamycin,
will be effective primarily in patients whose tumors are
dependent on the molecule being targeted. For
example, the results of work from multiple investi-
gators
58–63 suggest that activation of PI3K signaling
through PTEN loss sensitizes tumor cells to rapamycin
in preclinical models, although other pathways that
modulate sensitivity have been described.
31 This
suggests that it may be possible to stratify patients for
treatment on the basis of PTEN status. Second, for tar-
geted agents that inhibit the activity of speciﬁc signaling
pathways, such as the mTORC1/S6K1/S6 signaling
axis, assays to assess the adequacy of pathway inhibition
need to be incorporated into the design, interpretation,
and implementation of clinical trials. Furthermore,
tumor tissue must be accessed at relevant time points
during treatment, which presents additional challenges
for clinical trial design.
Salvage surgical resection is often part of treatment
for glioblastoma patients who experience relapse after
standard up-front therapy. This clinical scenario pre-
sents opportunities for trials that include molecular-
based selection criteria. In collaboration with Drs Tim
Cloughesy, Charles Sawyers, Ingo Mellinghoff, and col-
leagues, we conducted a small pilot phase I and II neoad-
juvant clinical trial of rapamycin in patients with
relapsed PTEN-negative glioblastoma. Rapamycin was
orally administered to patients prior to a scheduled
tumor resection, with the primary goals of deﬁning the
dose required for mTOR target inhibition and assessing
potential anti-proliferative effects on tumor cells. PTEN
status in tumor tissue was determined at initial clinical
presentation and biopsy evaluation. After relapse,
patients with PTEN-deﬁcient tumors at biopsy received
a 10-day course of rapamycin at 1 of 3 dosages (2, 5,
or 10 mg/day b.i.d.), followed by surgical excision.
Intratumor drug levels, mTORC1 signaling (as
measured by S6 phosphorylation), and cellular prolifer-
ation were measured and compared between both surgi-
cal procedures in rapamycin-treated patients and in a set
of similarly matched “control” patients with relapsed
glioblastoma who had not undergone rapamycin
treatment.
Intratumoral rapamycin concentrations sufﬁcient to
inhibit mTOR in vitro were achieved in all patients,
even at the lowest dose. However, the magnitude of
mTORC1 inhibition in tumor cells varied signiﬁcantly
from patient to patient, irrespective of dose (10%–
80% inhibition of S6 phosphorylation). Reduced
tumor cell proliferation (as measured by Ki67 staining)
in vivo was signiﬁcantly related to the degree of inhi-
bition of mTORC1 signaling. mTORC1 inhibition of
more than 50% resulted in signiﬁcantly inhibited
tumor cell proliferation; lower inhibition did not result
in a cytostatic response. Signiﬁcantly, ex vivo-cultured
tumor cells from rapamycin-“resistant” patients were
highly sensitive to the drug, suggesting that rapamycin
resistance is not cell autonomous but rather due to a
failure of the drug to fully access its target in vivo.
Pathway Cross-Talk and Feedback Loops in
Patients
To determine whether rapamycin treatment promotes
tumor cell growth in patients by repressing the negative
feedback loop for attenuating PI3K signaling,
64,65




with signiﬁcantly shorter time-to-progression during
postsurgical rapamycin maintenance therapy.
41 Thus,
understanding the complex role of mTOR in regulating
signal transduction and cellular metabolism (as
discussed below) is critical to developing more effective
mTOR-targeted therapies.
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Inhibition
The ﬁnding of PI3K pathway reactivation after rapamy-
cin treatment suggests that dual PI3K/mTOR inhibitors
function by preventing PI3K signaling reactivation and
more effectively target TORC2 (and TORC1) signaling.
A dual PI3K/mTOR inhibitor (PI-103) was shown to be
efﬁcacious at blocking the growth of glioblastoma cells
in vitro and in vivo, independent of PTEN status.
53
The combination of this inhibitor and erlotinib or geﬁti-
nib also resulted in a signiﬁcant beneﬁt in EGFR-
activated tumor cells.
54 A number of dual PI3K/
mTOR inhibitors are being evaluated in early clinical
trials, including NVP-BEZ235, which has shown efﬁ-
cacy against a panel of glioblastoma cell lines.
66
Somewhat surprisingly, in preclinical glioblastoma
models, dual PI3K/mTOR inhibitors have failed to
promote tumor cell apoptosis.
66 Investigations are
underway to determine whether these dual PI3K/
mTOR inhibitors will promote apoptosis when used in
conjunction with other pathway-targeted agents, cyto-
toxic chemotherapies, or radiation therapy.
The remarkable plasticity of tumor cells and their
capacity for rewiring was recently demonstrated in
studies that found mTORC1 inhibition leads to ERK
pathway activation through a PI3K-dependent mechan-
ism.
12 The results of these studies indicate that dual
PI3K/mTOR inhibitors may also suppress ERK signal-
ing activation. A similar “biopsy-treat-biopsy” strat-
egy
41 to that described above may be required to assess
the effect of dual PI3K/mTOR inhibitors on PI3K,
mTORC1, mTORC2, Akt, and ERK signaling and
assess their clinical beneﬁts. Such studies will help deter-
mine the use of these agents, alone or in combination
with other pathway-targeted agents, cytotoxic therapies,
or radiation therapy.
mTOR at the Interface of Signal
Transduction and Cellular Metabolism
Up to this point, studies of mTOR have focused on its
role as a key effector and regulator of PI3K signaling.
However, mTOR also plays a critical role in integrating
cellular metabolism with signal transduction. Sarah
Kozma’s and George Thomas’ research groups demon-
strated that class 3 PI3K (vps34) provides an amino acid-
sensing mechanism to activate mTORC1 signaling in a
process that is entirely independent of class I PI3K and
its canonical signaling pathway.
67 This observation indi-
cates that mTOR is a key node for integrating growth
factor signaling with cellular metabolism. It also raises
the possibility that class 3 PI3K signaling to mTORC1
could promote escape from mTOR or dual class I
PI3K/mTOR inhibitors. Further studies are needed to
address the clinical relevance of class 3 PI3K signaling
to mTOR in glioblastoma patients and to assess its con-
tribution towards promoting clinical resistance to RTK/
PI3K/mTOR inhibitors.
mTORC1 has also emerged as a critical effector
downstream of the tumor suppressor liver kinase B1
(LKB1, also referred to as STK11). The germline loss
of LKB1 is responsible for Peutz-Jeghers inherited
cancer syndrome, and its sporadic loss has been detected
in a variety of cancers.
68 LKB1 is thought to suppress
tumors by negatively regulating mTORC1 signaling via
the central metabolic switch, AMP-activated protein
kinase (AMPK). The LKB1-AMPK pathway acts as a
metabolic checkpoint that arrests cell growth when
nutrients are scarce. LKB1 phosphorylates and activates
AMPK, which in turn negatively regulates mTORC1 sig-
naling through the activation of TSC2 and the direct
inhibitory phosphorylation of the mTOR binding
partner raptor.
69–71 Further, in tumors caused by
LKB1 loss,
68,72 mTOR may play a key role downstream
of LKB1/AMPK metabolic signaling.
Other classic growth factor signaling pathways may
also interact with LKB1/AMPK. Recent studies have
demonstrated that the B-RAF V600E mutation, a
common hyperactivating mutation in melanoma and
other cancer types,
73–75 forms a complex with Erk and
LKB1 that promotes phosphorylation and inactivation
of LKB1 by ERK, thus functionally suppressing
LKB1’s ability to activate AMPK and activating
mTORC1.
76 Strikingly, LKB1 that lacks V600E BRAF
phosphorylation sites (s325 and s428) inhibits
V600E-driven proliferation, suggesting that the LKB1/
AMPK axis is a critical mediator of oncogenic RAF
signaling.
76
The role of LKB1/AMPK signaling and the impor-
tance of mTORC1 as LKB1/AMPK’s mediator in malig-
nant gliomas remain to be elucidated. A recent study
by our research group demonstrated that the AMPK
agonist AICAR is very effective at blocking the growth
of EGFR-activated glioblastomas, both in vitro and
in vivo.
40 Surprisingly, this was only partially mediated
by inhibition of mTORC1 signaling. Rather, the striking
anti-growth effect of AICAR on EGFR-activated tumor
cells was mediated primarily by inhibiting lipogenesis.
Understanding how AMPK regulates lipogenesis and
how it interacts with mTORC1 signaling, as well as
with EGFR signaling through the PI3K/Akt and
RAS/ERK pathways, may prove important for develop-
ing more effective treatment strategies.
77
EGFR Regulation of Lipogenesis
Rapidly dividing cancer cells require a supply of fatty
acids for the formation of new cellular membranes. In
addition, fatty acids may be very important for regulat-
ing signal transduction, and they provide an alternative
energy source for the cell. It appears that de novo syn-
thesis of fatty acids is the preferred route for cancer
cells. This suggests that an important link exists
between cancer progression and fatty acid synthesis
and that targeting fatty acid synthesis could be an effec-
tive way to block cancer growth. However, the molecu-
lar circuitry linking oncogenes and tumor suppressor
proteins and the pathways they regulate, along with
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stood. An improved understanding of the relationships
between cancer-associated genes and cellular metab-
olism could lead to new cancer treatments.
We recently demonstrated that EGFR signaling pro-
motes activation of the transcriptional regulator of
fatty acid synthesis, SREBP-1.
77,80 This was ﬁrst discov-
ered in glioblastoma tissue samples from patients treated
with the dual EGFR/Her2 kinase inhibitor lapatinib.
We compared tissue samples before and after lapatinib
treatment and found that tissue that exhibited a response
to lapatinib, as demonstrated by a decrease in p-EGFR,
showed a concomitant decrease in SREBP-1 staining.
Expanding on this observation through the use of a
series of glioblastoma cell lines, we observed that
EGFR signaling promoted cleavage and nuclear translo-
cation of SREBP-1, with increased transcriptional acti-
vation of its downstream target fatty acid synthase and
increased amounts of intracellular fatty acids.
Most importantly, we found that abundant EGFR
signaling makes glioblastoma cells more dependent on
fatty acid synthesis. As a consequence, interruption of
fattyacidsynthesis,eitherby blocking SREBP-1 cleavage
or by blocking the activity of the fatty acid synthase
enzyme, causes massive apoptotic cell death in tumors
with abundant EGFR signaling but not in those with
little EGFR signaling. Surprisingly, this phenomenon
was independent of mTORC1, although its pathway
dependence on mTORC2 has yet to be explored.
Concluding Thoughts
Because it is a key mediator of PI3K signaling and an
integrator of signal transduction and cellular metab-
olism, mTOR represents an attractive therapeutic
target for glioblastoma. Despite the relative clinical
failure of rapamycin and its derivatives, an enormous
amount has been learned fromstudying mTOR signaling
in well-controlled experimental glioma models and
rapamycin and its analogues in phase I and II clinical
trials. However, a number of challenging questions
havebeen raised. Do wefully understand the importance
of mTORC2 signaling in malignant gliomas, and is
dependence on this pathway enhanced in the context
of persistent PI3K signaling? What is the role of class
III PI3K signaling to mTORC1 in malignant gliomas,
and does this pathway play a role in promoting resist-
ance to growth factor receptor and class I PI3K targeted
therapies? To what extent is mTORC1 the critical effec-
tor of LKB1/AMPK signaling in malignant gliomas, and
if so, is AMPK’s dependence on mTORC1 mediated by
cell context? Will true mTOR kinase inhibitors prove
to be more effective than rapamycin and its derivatives?
Will PTEN status matter? Will dual PI3K/mTOR inhibi-
tor treatments be needed, and will these agents suppress
feedback activation of ERK signaling, or will their efﬁ-
cacy depend on the concurrent use of ERK inhibitors?
Will it be possible to develop better AMPK agonists
that cross the blood-brain barrier, and will they be effec-
tive at blocking mTORC1 signaling and glioblastoma
tumor growth? Answers to these questions, along with
emerging data about the underlying molecular circuitry
and the development of true mTOR kinase inhibitors,
will result in an array of new treatment approaches.
Perhaps most importantly, well-designed clinical trials
are needed in which tissue can be accessed at relevant
time points to analyze pathway activation biomarkers.
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